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Abstract
Purpose—Platinum-based therapies are the first line treatments for most types of cancer 
including ovarian cancer. However, their use is associated with dose-limiting toxicities and 
resistance. We report initial translational studies of a theranostic nanoemulsion loaded with a 
cisplatin derivative, myrisplatin and pro-apoptotic agent, C6-ceramide.
Methods—The surface of the nanoemulsion is annotated with an endothelial growth factor 
receptor (EGFR) binding peptide to improve targeting ability and gadolinium to provide 
diagnostic capability for image-guided therapy of EGFR overexpressing ovarian cancers. A high 
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shear microfludization process was employed to produce the formulation with particle size below 
150 nm.
Results—Pharmacokinetic study showed a prolonged blood platinum and gadolinium levels with 
nanoemulsions in nu/nu mice. The theranostic nanoemulsions also exhibited less toxicity and 
enhanced the survival time of mice as compared to an equivalent cisplatin treatment.
Conclusions—Magnetic resonance imaging (MRI) studies indicate the theranostic 
nanoemulsions were effective contrast agents and could be used to track accumulation in a tumor. 
The MRI study additionally indicate that significantly more EGFR-targeted theranostic 
nanoemulsion accumulated in a tumor than non-targeted nanoemulsuion providing the feasibility 
of using a targeted theranostic agent in conjunction with MRI to image disease loci and quantify 
the disease progression.
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INTRODUCTION
Ovarian carcinoma is the most common cause of death from gynecologic malignancy and is 
frequently associated with a poor outcome due to the difficulties of early diagnosis (1, 2). 
For ovarian cancer, platinum-based drugs - carboplatin and cisplatin - increase overall 
survival and tumor free survival better than any other chemotherapeutic drug (3). However, 
their clinical use is still limited due to intrinsic and acquired resistance (4) and generalized 
toxicity, including acute nephrotoxicity, chronic neurotoxicity and adverse gastrointestinal 
reactions (5). Recurrent ovarian cancer is classified as been platinum resistant, defined as 
relapsing within 6 months, or platinum sensitive, defined as relapsing more than 6 months 
after completing initial platinum-based chemotherapy (6). Treatment decisions based on a 
cancer being “platinum-sensitive” or “platinum-resistant” underscoring the important role 
that platinum-based chemotherapy has in the treatment of this disease.
It has been envisioned that use of polymeric conjugates or nanocarrier-based systems may 
provide improved solubility of platinum-based chemotherapies, prolong half-life in 
circulation, increase tumor accumulation, decrease non-specific toxicity of platinum-based 
chemotherapies and potentially reduce the development of drug resistance (7). Thus, various 
polymeric conjugates and liposomes, micelles, dendrimers, and other carriers have been 
studied for delivery of platinum compounds (8–11). Cisplatin-loaded liposomes (lipoplatin) 
reduced tumor burden comparable to cisplatin and showed improved toxicity profile because 
of the slower release and lower exposure of platinum to normal tissues (12). However, this 
slower release characteristics also resulted in fewer platinum-DNA abducts from forming 
thus it was shown to have low clinical advantage over the standard of care platinum 
therapies (13).
The insolubility of cisplatin in organic solvents and solubility in water pose challenges to 
encapsulate and control release of platinum-based derivatives in nanomedicines. We 
recently reported novel hydrophobic platinum-derivatives by attaching myristic acid to 
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cisplatin (myrisplatin) which was encapsulated in the oil core of a stable nanoemulsion (14). 
Nanoemulsions are colloidal carriers formed by dispersion of oils in water and stabilized 
with an amphiphilic phospholipid monolayer (15–19). Significant amounts of hydrophobic 
drug can be loaded in the high volume fraction of the oil core in nanoemulsion (17, 19, 20). 
The nanoemulsions we investigate are usually composed entirely of generally regarded as 
safe grade (GRAS) materials, which have highly favorable safety profiles. Due to their small 
size (less than 200 nm), nanoemulsions are expected to preferentially accumulate in tumors 
via the enhanced permeability and retention (EPR) effect (21). The surface of the 
nanoemulsion can be modified with ligands for active targeting to tumors. The usefulness of 
nanoemulsions to improve delivery of chemotherapeutic payload for the treatment of 
ovarian cancer has been demonstrated by us (20, 22–25).
Theranostic nanomedicines are the state-of the art in molecular design and engineering to 
develop systems that can be used effectively for the detection, diagnosis, and treatment of 
cancer. Theranostic nanoemulsions can be engineered to have these capabilities in an all-in-
one platform, which include protection and controlled release of a therapeutic payload, 
targeted delivery and diagnostic functionality. Our nanoemulsions formulations can be 
surface annotated with gadolinium, a magnetic resonance imaging (MRI) contrast agent and 
has been shown to have relaxation times comparable to Magnevist® (14, 20). Folate-targeted 
nanoemulsions accumulated in tumors for prolonged period of time compared to 
Magnevist® and showed enhanced contrast compared to non-targeted nanoemulsions with 
MRI in SKOV-3 tumor-bearing mice suggesting active targeting of nanoemulsions due to 
folate modification (20).
In our previous work we developed a novel EGFR-targeted, gadolinium-annotated-
theranostic nanoemulsions that co-delivers myrisplatin and C6-ceramide (a proapoptotic 
agent) which is capable of overcoming platinum resistance in vitro and is an effective 
contrast agent (14). In this paper we describe the initial translational studies articulating 
imaging, safety, and efficacy capacity of this novel theranostic nanoemulsion.
MATERIALS AND METHODS
Materials
A hydrophobic platinum conjugate, myrisplatin was synthesized at the Nemucore Medical 
Innovations, Inc., (Worcester, MA) using published routes (14, 26). Gadolinium chelate 
gadolinium-diethylenetriaminepentaacetic acid-phosphatidylethanolamine (gadolinium-
DTPA-PE) to incorporate into nanoemulsions for MRI functionality was synthesized as 
described previously (14). EGFR targeting ligand was synthesized as reported previously 
(14, 24). The details regarding synthesis, purification and characterization of these 
conjugates were reported in our recent publication (14). Cisplatin (cis-diammineplatinum 
(II) dichloride) was from Sigma Chemicals (St. Louis, MO). C6-ceramide (N-hexanoyl-D-
erythro-sphingosine) was purchased from Avanti Polar Lipids (Alabaster, AL). Egg 
phosphotidylcholine (Lipoid® E80) was obtained from Lipoid GmbH (Ludwigshaffen, 
Germany). The pegylating agent, methoxy-poly(ethylene glycol)-2000 distearoyl-sn-
glycero-3-phosphoethanolamine, sodium salt (PEG2000DSPE) was purchased from Lysan 
Bio Inc. (Arab, AL). Poly unsaturated fatty acid (PUFA) rich flax seed oil was received 
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from Puritan’s Pride Inc. (Oakdale, NY). All other chemicals and solvents used were of the 
highest available grade.
Formulation and characterization of theranostic nanoemulsion
Theranostic nanoemulsion formulation for image-guided therapy consisting of myrisplatin 
and C6-ceramide in its lipid core and imaging and targeting moieties on the surface was 
prepared by high shear microfluidization process using LV1 Microfluidizer (Microfluidics 
Corporation, Newton, MA). The aqueous phase of the formulation was prepared by 
dissolving egg lecithin (2.4% w/v) and PEG2000DSPE (0.3% w/v) in 4 ml of glycerol 
(2.21% w/v)-water. To which, gadolinium-DTPA-PE (2% w/v) and EGFR targeting ligand 
(0.1% w/v) were added and stirred for 1 h to achieve uniform dispersion of all components. 
Oil phase was prepared by mixing of flax seed oil with the desired amounts of myrisplatin 
and C6-ceramide dissolved in chloroform, and evaporating the solvent using nitrogen gas, 
resulting in drug solubilized lipid phase. After this, aqueous and oil phases were heated 
(60°C, 2 min), mixed and then homogenized at 25,000 psi for 10 cycles to obtain the oil-in-
water theranostic nanoemulsion formulations. Non-targeted nanoemulsions were prepared 
by omitting EGFR targeting ligand from above listed procedure whereas blank 
nanoemulsions were prepared by omitting EGFR targeting ligand as well as myrisplatin and 
C6-ceramide.
The platinum concentration in formulations was determined by Inductively Coupled Plasma-
Mass Spectrometry (ICP-MS) (14). Gadolinium concentration was monitored by 
colorimetric method using arsenazo III dye assays as described previously (14, 27). T1 
relaxation times of gadolinium nanoemulsions formulations were measured using Magnetic 
Resonance Imaging (MRI). For T1 measurements, nanoemulsion sample in tubes were 
subjected to a phantom Brucker 500 MHz MRI machine (Bruker Biospec 20/70, Bruker 
Biospin MRI, Inc, Billerica, MA) in a 4.7 Tesla magnetic field, creating MRI scans showing 
nanoemulsion generated contrast as well as T1 time measurements. For comparison 
Magnevist®, a gadolinium-DTPA chelate, was also analyzed for T1 relaxation time at the 
same gadolinium concentration as the Gadolinium annotated-nanoemulsions.
Size distribution of all nanoemulsion formulations was determined by dynamic light 
scattering method. For this, samples were diluted 1000 times in deionized distilled water, 
and the droplet size was determined at 90° angle using Zetasizer ZS (Malvern, UK). 
Polydispersity index (PDI) was used as a measure for calculating particle size istribution. 
The zeta potential value of nanoemulsion was also determined using Zetasizer ZS. 
Nanoemulsion samples diluted in distilled water were placed in electrophoretic cell and the 
zeta potential measured basing on the electrophoretic mobility of the nanoemulsion droplets.
Pharmacokinetics and tissue distribution
All the animal study protocols were approved by the Northeastern University’s Institutional 
Animal Care and Use Committee. Pharmacokinetics and tissue distribution of platinum and 
gadolinium were performed in nu/nu mice (female, 20–25 g) purchased from Charles River 
Laboratories (Cambridge, MA). Mice divided into groups having three mice in each group 
received either intravenous (IV) via tail vein or intraperitoneal (IP) administration of non-
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targeted and EGFR-targeted theranostic nanoemulsions with myrisplatin dose equivalent to 
5 mg/kg of platinum. Whereas gadolinium dose was 0.072 mmoles/kg. A group of mice 
were also administered cisplatin at 10 mg/kg IV vial tail vein. Three mice from each group 
at various time points (5, 15, 30 min, and 1, 2, 4, 6 and 24 h) were anaesthetized with 
isoflurane and blood collected from the cardiac puncture into heparin treated tubes. The 
blood samples were then centrifuged at 3500 rpm for 15 min, the plasma removed and 
stored at −20 °C until analyzed for platinum and gadolinium using ICP-MS at University of 
North Carolina, Chapel Hill, NC. After blood collection, the mice were euthanized by 
cervical dislocation, and liver, kidney, heart, lungs and brain were removed. Tissues were 
stored at −20 °C until analyzed for platinum and gadolinium using ICP-MS.
For all treatments, 100 μL of 70% HNO3 with 100 ng/mL of Iridium was added to 50 μL of 
plasma for sum total metal detection. Samples were digested at 100 °C for 90 minutes. 
Filtered water was added to make a final volume of 1,000 μL for all plasma samples and 
stored at 4 °C until analysis.
For cisplatin samples, tissues were processed to measure total cisplatin as described above. 
The plasma was processed to measure total and unbound cisplatin. An additional 150 μL of 
plasma was required for unbound cisplatin concentration detection. Plasma was added to 
ultracentrifugation chamber and spun at 2500g for 30 minutes at 25 °C. After centrifugation, 
50 μL of ultrafiltration was collected and process like sum total plasma previously 
described. For tissue sum total gadolinium and Pt detection, a goal weight of 60 to 80 mg 
was collected. After weight was recorded, 100 μL of 70% HNO3 with 200 ng/mL of Iridium 
was added to each tissue. Tissues were digested at 100 °C for minimum 2 hrs and filtered 
water was added for final volume of 2,000 μL and stored at 4 °C until analysis.
ICP-MS elemental analysis was performed on an Agilent 7500cx (Agilent Technologies, 
Tokyo, Japan). Instrumental parameters were optimized daily to obtain best sensitivity 
before analysis. The lower limit of detection for gadolinium, platinum and Iridium was 1.0 
ng/mL. Indium was used for the external instrument standard.
Pharmacokinetic analysis
Pharmacokinetic parameters of platinum and gadolinium were estimated using WinNonlin 
(Phoenix version 6.0) program (Pharsight Corporation, USA). The mean residence time 
(MRT), the volume of distribution (Vd), total body clearance (Cl) and plasma half-life for 
the elimination phase (t1/2) were calculated by non-compartmental analysis (NCA) using 
weighed least square algorithm with uniform weighing. The area under the plasma and 
tissue concentration-time profiles (AUC) was calculated by the linear up log down.
MRI study
MRI was performed on female nu/nu mice (20–25 g) bearing subcutaneous flank SKOV-3 
tumors. Female nu/nu mice (20–25 g) were injected subcutaneously with 4×106 SKOV-3 
ovarian cancer cells suspended in 100 μL PBS (1:1 ratio of PBS and Matrigel HC) under 
light isoflurane anesthesia. After the tumor volume reached around 200–300 mm3, the mice 
were injected (n=3) IV via tail vein with MRI contrast agent gadolinium at 0.072 mmoles/kg 
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in non-targeted, EGFR-targeted nanoemulsions, or Magnevist®, (a clinically used 
gadolinium-DTPA chelate) and imaged under MRI over 24 h period using a phantom 
Brucker 500 MHz MRI machine (Bruker Biospec 20/70, Bruker Biospin MRI, Inc, Billerica, 
MA) in a 4.7 Tesla magnetic field. MRI scans showing nanoemulsion generated contrast in 
T1-weighted images was obtained. Magnevist® was used as a clinically relevant control 
imaging agent compared with nanoemulsions to detect changes in contrast efficiency and/or 
distribution.
Therapeutic efficacy in tumor bearing mice
Female nu/nu mice (20–25 g) were injected subcutaneously with 4×106 SKOV-3 ovarian 
cancer cells suspended in 100 μl PBS (1:1 ratio of PBS and Matrigel HC) under light 
isoflurane anesthesia. After the tumor volume reached around 150 mm3, the mice were 
randomly divided into four groups (n=6) and treated with vehicle (Control group), cisplatin 
solution, non-targeted and EGFR targeted theranostic nanoemulsions on a schedule of every 
7 days × 5. Treatment groups received first 3 cycles of 5 mg/kg platinum and additional 2 
cycles of 7.5 mg/kg platinum. Mice were monitored for tumor growth, survival time and 
change in body weight following the treatment.
DATA ANALYSIS
Data are reported as the average and standard deviation. Comparisons between the groups 
were made using student’s t-test and with more than two groups, the ANOVA test was used. 
Values of p < 0.05 were considered statistically significant.
RESULTS
Preparation and characterization of theranostic nanoemulsions
Theranostic nanoemulsion with imaging and targeting functionality, and co-encapsulating 
myrisplatin and C6-ceramide was prepared using high shear microfluidization process. The 
oil-in-water formulation was composed of flaxseed oil as an oil core in which myrisplatin 
and C6-ceramide were solubilized. Flax seed oil was emulsified in a glycerol-water using 
egg lecithin as an emulsifier. Glycerol was added to the formulation to obtain the osmolality 
required for IV administration (17). EGFR-targeting ligand and gadolinium-DTPA-PE were 
dissolved into glycerol-water, and when emulsified into oil, the lipid portion of these 
conjugates go into the oil core and EGFR and gadolinium remain on the surface of 
phospholipid monolayer and extends into aqueous phase as described earlier (14). 
PEG2000DSPE was also incorporated in the formulation to reduce mononuclear phagocyte 
(MNP) based clearance and promote longer blood circulation. Optimized microfludization 
conditions of 25,000 psi and 10 cycles were employed to obtain the particle size of 
formulations below 150 nm with narrow size distribution as reported earlier (14).
Particle size and zeta potential values of the theranostic nanoemulsions are showed in Table 
I. The mean hydrodynamic particle size of blank, non-targeted and EGFR-targeted 
formulations was about 150 nm with the PDI below 0.1, suggesting a narrow distribution of 
particle size in the formulations. Zeta potential measurements of formulations showed a 
surface charge in the range of −49 to − 59 mV. T1 relaxivities were determined using MRI. 
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T1 value of Magnevist® is 22 msec. As seen from Table I, the contrast efficiency of 
theranostic nanoemulsions is in the close range and comparable to Magnevist®.
Pharmacokinetics and tissue distribution analysis
The plasma concentration-time curves for platinum and gadolinium after the IV and IP 
administration of theranostic nanoemulsions and cisplatin are shown in Figure 1 and 2 with 
calculated pharmacokinetic parameters reported in Table II and III. Results show that IV 
administration resulted in an initial Cmax for non-targeted and EGFR targeted 
nanoemulsions, with platinum levels declined slowly over time (Figure 1) resulting in an 
observed significantly longer elimination-half lives in mice. Cisplatin also showed an initial 
Cmax but blood concentrations of protein bound and elemental platinum cleared at a much 
faster rate than either nanoemulsion (Figure 1). Gadolinium blood levels were also declined 
slowly and tracked with platinum suggesting the gadolinium was not separated out from the 
formulation in the blood circulation (Figure 2). This property is important for the 
nanoemulsion to remain functional for an extended period of time to provide effective tissue 
contrast by MRI. IP administration showed blood concentrations (Cmax) peaking at 3 h 
(Table II and Table III) and nearly identical levels to IV treated mice for both platinum and 
gadolinium. Cmax is not significantly different between non-targeted and EGFR targeted 
systems for both platinum and Gadolinium levels. However, 2–5-fold difference in Cmax 
was observed between IP and IV routes of administration. This difference may be due to 
nanoemulsion controlling drug release some extent so that the absorption was delayed when 
delivered through IP route. Overall, the plasma pharmacokinetic profile of platinum was 
improved when administered in nanoemulsion as compared to cisplatin.
Tissue (liver, kidney and lungs) concentrations of platinum and gadolinium after the 
administration of EGFR-targeted nanoemulsions are shown in Figure 3. In general 
significant amounts of platinum and gadolinium levels were noted in liver for 
nanoemulsions due reticuloendothelial uptake of nanoparticles. After administration of 
cisplatin the highest exposures occur in the kidney which is consistent with prior studies 
(28).
MRI study
Gadolinium chelates typically provide contrast in tissue compartments in which it is 
concentrated in T1-weighted images. Figure 4A and 4B shows tumor accumulation of 
theranostic nanoemulsions following IV injection. Magnevist® rapidly accumulates and 
clears from the tumor within 6 h, while the non-targeted and EGFR- targeted nanoemulsion 
accumulate in the tumor for longer duration up to 24 h. However, EGFR-targeted 
nanoemulsion showed enhanced contrast, suggesting slower clearance rate as compared to 
non-targeted nanoemulsion. Moreover, the T1-weighted images show that the EGFR-
targeted nanoemulsion distributes uniformly across the tumor compared to non-targeted 
nanoemulsion as well as Magnevist®, Figure 4A. The relative T1 signal generated by Gd in 
the tumor region of interest was used to determine uptake. EGFR-targeted nanoemulsion and 
non-targeted nanoemulsion showed tumor tissue accumulation over the period of 24 h 
Figure 4B. The EGFR-targeted nanoemulsion showed enhanced accumulation in tumor 
tissue compared to non-targeted nanoemulsion. Clinically used magnevist accumulated in 
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tumor tissues very rapidly and cleared within 5 h Fig 4B. These results indicate the EGFR-
targeted theranostic nanoemulsion was effective contrast agent for MRI and the feasibility of 
using MRI to localize the disease and quantify the disease progression of solid tumors. This 
data also demonstrates that theranostic nanoemulsions with its payload in the EGFR-targeted 
nanoemulsion will show a similar accumulation and residence profile in the EGFR+ tumors, 
which can potentially increase therapeutic efficacy. These results when taken with the 
pharmacokinetic data showing that platinum and gadolinium have similar clearance profiles 
suggest that the gadolinium based tumor contrast in MRI (Figure 4) is a good surrogate 
marker for platinum accumulation in the tumor.
Therapeutic efficacy
The mean survival time was evaluated in mice bearing SKOV-3 ovarian tumors and 
compared to cisplatin therapy (Figure 5A). Mice in the control group reached tumor 
volumes of approximately 1000 mm3 at 21 days, the survival end point for the study, and 
were removed from the study. However, treated groups survived longer, and the survival 
times were 21, 25, 32 and 32 days with control, cisplatin, non-targeted and EGFR-targeted 
nanoemulsions, respectively. Mice were administered with 5 mg/kg of Pt on every week for 
three weeks, later the dose was increased to 7.5 mg/kg based on tumor response and 
continued for 4th and 5th week. Toxic effects in cisplatin treated mice were evident, as mice 
lost 20% of their body weight and were sacrificed (Figure 5B). However, the mice in the 
non-targeted and EGFR-targeted theranostic nanoemulsion groups did not lose significant 
weight and their physical activity was normal. These results suggest that mice tolerated a 
high dose of Pt given in the nanoemulsion formulations.
DISCUSSION
Recurrent cancers develop multidrug resistance (MDR) to conventional and novel 
chemotherapeutic agents representing a formidable challenge in clinical cancer therapy, 
especially for the effective treatment of gynecological malignancies, which are generally 
diagnosed at a late stage. Ovarian cancer is the most lethal of the gynecologic cancers due to 
its propensity to spread into the upper abdomen and beyond, and a majority of newly 
diagnosed ovarian cancer patients will progress to a chemo-resistant state. Platinum 
containing therapeutic compounds are alkylating agents that exert anticancer activity by 
disrupting DNA structure in cell nuclei through the formation of intrastrand and interstrand 
cross-links (29–31). Cisplatin is used to treat ovarian cancer patients, but there is significant 
dose related nephrotoxicity. Carboplatin, which has virtually replaced cisplatin for patient 
treatment, forms reactive species more slowly than cisplatin and has a much better, but still 
significant, toxicity profile including renal damage, electrolyte loss, nausea and vomiting.
Toxicity and platinum-resistance are the driving force to identify safer, more effective and 
selective platinum therapy. Strategies include preparing hydrophobic prodrugs, platinum-
polymer conjugates or encapsulating them into nanocarrier formulations for targeted and 
controlled release (32–34). Lipoplatin, a cisplatin liposomal formulation, was tested in phase 
I–III clinical trials, and showed a significantly improved toxicity profile and a reduction in 
tumor burden comparable to that of free cisplatin but overall it has not proven to be more 
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efficacious (12, 35). STEALTH liposomal cisplatin formulations were developed for the 
treatment of cancers that are generally sensitive to platinum, but may be resistant to 
conventional cisplatin, and reduce toxicities by preferentially delivering drug to the tumor. 
Even though there is a several-fold higher exposure of total Pt in tumors compared to 
cisplatin, this did not translate into significant antitumor response in clinical trials (13, 36). 
These results suggest that formulations distribute into tumors, but release less platinum and 
form fewer platinum-DNA adducts than cisplatin (13).
Innovation in platinum encapsulation and controlled release are still a challenge due to 
physicochemical properties of platinum compounds. Lipophilicity is a critical parameter for 
design of novel platinum-based drugs to improve absorption and transport through 
membranes (37). In a recent study, a platinum prodrug was synthesized that had enough 
hydrophobicity for encapsulation in PLGA-b-PEG nanoparticles, which was found to be 
safe and effective (32). Recently platinum compounds containing a monocarboxylate and O 
-> Pt complexation resulted in a faster release of DNA reactive adducts comparable to 
cisplatin (34), and formed the basis for designing some lipophilic platinum derivatives 
suitable for nanoemulsion encapsulation. In this paper, we report initial in vivo data of a 
theranostic nanoemulsion with a cisplatin derivative, myrisplatin and pro-apoptotic agent, 
C6-ceramide for image-guided therapy of EGFR overexpressing ovarian cancer.
Our strategy for platinum therapy focuses on the development of lipophilic platinum 
conjugates that can be incorporated into the oil core of long-circulating targeted 
nanoemulsions. Our platinum chemistry involves the synthesis of hydrophobic platinum 
tailed with a myristic acid. Another reason for encapsulation of platinum in a nanoemulsion 
is to design additional features into the delivery system that could assist in mitigating 
platinum-resistant mechanisms. Mechanisms of platinum resistance include: reduced 
platinum influx, increased platinum efflux, escape from apoptosis, sequestration by chemical 
conjugation, or increased DNA repair (38). The present nanoemulsion is designed to 
enhance platinum influx by receptor-mediated endocytosis, potentially reduce platinum 
efflux and diminish escape from apoptosis.
Table II and Table III highlights the enhanced pharmacokinetic profile of platinum/
gadolinium delivered by either targeted or non-targeted nanoemulsions administered either 
IV or IP All parameters suggest the both formulations are long circulating and remain intact. 
Notably there is a significant increase in half life of the platinum/gadolinium compared to 
cisplatin. The biodistribution profile of platinum and gadolinum was also comparable. The 
nanoemulsion mainly accumulated in liver which is the common elimination pathway for 
nanocarriers (Figure 3). Even though still consistent with long-circulation, we also observed 
a difference in the half life of gadolinium compared to platinum in the nanoemulsions. We 
attribute this difference to the way the nanoemulsions were designed to have the 
gadolinium-DTPA chelating moiety exposed on the surface so it could function as contrast 
agent while myrisplatin is sequestered inside the oil droplet to abrogate platinum binding to 
serum protein to mitigate systemic toxicities. The gadolinium chelation mechanism with 
DTPA-PE conjugate includes a coordination with a free water molecule which could be 
responsible for premature release of gadolinium from the particle and difference in half life 
exhibited by these formulations.
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Encapsulation of the prodrug, myrisplatin, in the lipid core of the nanoemulsion protects the 
platinum from the elemental platinum-efflux mechanisms. To enhance influx the surface of 
the nanoemulsion was functionalized with an EGFR binding peptide, which preferentially 
binds with high affinity to the EGF receptor and undergoes receptor-mediated endocytosis 
of the targeted nanoemulsion. In light of the correlation with poor clinical outcome we 
previously investigated whether targeting EGFR could enhance in vitro potency (14). EGFR 
targeting was achieved through the use of a lipidated-version of a 12 amino acid peptide that 
has demonstrated efficient binding and preferential internalization into EGFR over 
expressing tumor cells in vitro, and tumor xenografts in vivo (24, 39–41). Our previous 
study found that EGFR targeting enhanced the potency of myrisplatin as compared to the 
non-targeted approach (14).
We examined the ability of the platinum carrying nanoemulsions to limit tumor growth of 
SKOV-3 cells in vivo. Non-targeted and EGFR-targeted nanoemulsions were used for the 
first time to deliver myrisplatin in combination with ceramides and slowed tumor growth 
comparable to cisplatin at equal doses. From our knowledge of the STEALTH liposomal 
cisplatin studies where platinum had difficulties releasing from the liposomes, we designed 
our in vivo efficacy experiment to directly compare equal doses of nanoemulsion 
encapsulated platinum to cisplatin. If we did not see any efficacy with this design then it 
might indicate nanoemulsion encapsulated myrisplatin was not releasing platinum to form 
DNA-platinum adducts. However, during our in vivo study we found that both targeted and 
non-targeted nanoemulsions had similar effects on growth of SKOV-3 xenograft tumors 
(data not shown) and improved survival compared to the cisplatin control group. Figure 5A 
shows that median survival for groups treated with non-targeted and targeted nanoemulsions 
was significantly different from control; while the cisplatin itself did not differ significantly 
from control. The dose escalation phase of the study indicated that non-targeted and EGFR-
targeted nanoemulsions did not induce the significant weight loss which the cisplatin cohort 
experienced. This indicates a potential for widening the therapeutic window for platinum 
therapies, since myrisplatin encapsulated nanoemulsions had significantly less systemic 
toxicity Figure 5B. The results indicate that therapeutic platinum is being released but 
EGFR-targeting is not improving efficacy in this initial assay which is counter intuitive 
given the results of the MRI study and needs to be investigated further.
A key challenge in ovarian cancer diagnosis and therapy is the ability to follow drug 
pharmacodynamics within the tumor region in real time. The nanoemulsions created for this 
study was designed as a theranostic, capable of simultaneously imaging and targeting drug 
delivery to EFGR-positive ovarian tumors. We designed our platinum-delivery vehicle so a 
relative imaging signal indicative of nanoemulsion uptake by a tumor shortly after IV 
injection and in a non-invasive manner by functionalizing the surface of the nanoemulsion 
with gadolinium-DTPA-PE chelate containing paramagnetic ion gadolinium for MRI 
contrast enhancement. This design with the gadolinium chelate residing on the outer surface 
of the nanoemulsion provides a suitable environment for gadolinium longitudinal relaxivity 
and generates contrast for MRI, thus allowing rapid visualization of drug 
pharmacodynamics and potentially quicker monitoring of disease progression in ovarian 
cancer patients.
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Previously we showed that non-targeted and targeted nanoemulsions have T1 values similar 
to those seen for clinically approved Magnevist®. We investigated whether nanoemulsion 
has the ability to effectively target subcutaneous EGFR+ SKOV-3 cells and enhance the T1 
signal of the tumor. SKOV-3 tumors were grown to 200–300 mm3, and serially imaged over 
24 hours. Figure 4A images show the resulting data of the entire mouse. Magnevist® rapidly 
accumulates in the tumor over the first hour and resolves to near baseline by the 6th hour. 
Non-targeted nanoemulsion primarily accumulates by the EPR effect enhancing tumor 
imaging over a longer period of time than Magnevist®. Targeted nanoemulsion takes 
advantage of both the EPR effect and active targeting of EGFR+ SKOV-3. EGFR-targeted 
nanoemulsions accumulate faster and have a longer resident time in the tumor than the other 
agents. This data suggest the therapeutic platinum/C6-ceramides should have a longer 
resident time in the tumor increasing the potential for a therapeutic response. Further 
investigations will have to be performed to understand the perceived differences between the 
efficacy and imaging studies.
Overall, this study demonstrates that the theranostic properties of a targeted platinum 
nanomedicine should be advantageous for the treatment of highly aggressive EGFR-positive 
ovarian cancer. As most ovarian cancers will eventually become platinum-resistant we have 
shown that co-delivery of myrisplatin and C6-ceramide provides a potential therapeutic 
option that is less toxic and has attributes designed to overcome platinum resistance by using 
receptor-mediated endocytosis to enhance particle accumulation as shown by MRI. The 
diagnostic potential of the nanoemulsion is designed for direct monitoring of nanomedicine 
tissue distribution and has potential for monitoring disese progression.
CONCLUSIONS
We developed a multifunctional nanodelivery platform consisting of the theranostic 
nanoemulsion with a cisplatin derivative, a novel platinum compound myrisplatin and pro-
apoptotic agent, C6-ceramide targeted with EGFR biding peptide and gadolinium for 
diagnostic capability. The formulation was effective and less toxic than cisplatin in treating 
a xenograft ovarian cancer model. These theranostic nanoemulsion formulations can be 
delivered at the same or greater dose than cisplatin and Magnevist® with no visual signs of 
toxicity. It will be interesting to see if distribution of imaging agent can be used to predict 
distribution of therapeutic agent and thereby can be used to predict therapeutic response in 
patients. This would be an important advancement in the treatment of platinum-resistance as 
physicians have a limited opportunity to find an effective therapy for patients with such 
advanced disease. While further preclinical efficacy, imaging and toxicology investigations 
are required to confirm these results, the medical utility of this novel nanomedicine 
configuration based on the initial results is promising.
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Platinum plasma concentration-time profile after IV via tail vein or IP administration of 
cisplatin, non-targeted and EGFR-targeted nanoemulsions to nu/nu mice. Myrisplatin dose 
in nanoemulsion equivalent to 5 mg/kg of platinum and 10 mg/kg for cisplatin. n=3.
Ganta et al. Page 15














Gadolinium plasma concentration -time profile after IV via tail vein or IP administration of 
non-targeted and EGFR-targeted nanoemulsion formulations to nu/nu mice. Gadolinum dose 
was 0.072 mmoles/kg. n=3.
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Free Cisplatin and platinum, gadolinium levels in tissues after IV administration via tail vein 
in nu/nu mice. Cisplatin dose was 10mg/kg. EGFR-targeted nanoemulsion were 
administered at myrisplatin dose equivalent to 5 mg/kg of platinum and 0.072 mmoles/kg of 
gadolinium. n=3.
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A. T1 weighted MR images and B. quantitative analysis of % tumor signal vs time of mice 
bearing subcutaneous SKOV-3 tumor xenograft post IV injection via tail vein of magnevist, 
non-targeted nanoemulsion and EGFR-targeted nanoemulsion. Arrows indicate 
accumulation of gadolinium in tumor tissue. n=3.
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A. Kaplan-Meier survival analysis and B. change in body weight on nu/nu mice bearing 
SKOV-3 ovarian tumors when injected with vehicle control, cisplatin alone, myrisplatin and 
C6-ceramide loaded non-targeted and EGFR-targeted theranostic nanoemulsions IV via tail 
vein. n=6, ± S.D.
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Table I
Properties of theranostic nanoemulsion formulations
Formulations
Hydrodynamic diameter of nanoemulsion droplets
Zeta Potential (mV) T1 Relaxivity (msec)
Size (nm) PDI
Blank nanoemulsion 150 ± 2 0.01 −52 ± 10 -
Non-targeted nanoemulsion 148 ± 6 0.05 −58 ± 11 35 ± 14
EGFR-targeted nanoemulsion 149 ± 3 0.06 −59 ± 13 47 ± 1
The values are shown as Avg ± SD, n=3.
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